Welcome to our dedicated page for HEARTFLOW news (Ticker: HTFL), a resource for investors and traders seeking the latest updates and insights on HEARTFLOW stock.
Heartflow, Inc. (Nasdaq: HTFL) is a medical technology company that uses artificial intelligence and coronary computed tomography angiography (CTA) to deliver non-invasive coronary artery disease (CAD) detection and management solutions. This news page aggregates company press releases and third-party coverage related to Heartflow’s technology, clinical research, reimbursement milestones, and corporate developments.
Readers can find updates on Heartflow’s Heartflow One platform, including FFRCT Analysis, Plaque Analysis, and PCI Navigator, as the company reports new clinical data, registry results, and real-world evidence. News items often highlight findings from large studies such as FISH&CHIPS and the DECIDE registry, which Heartflow cites to demonstrate prognostic value, changes in medical management, and potential cost savings associated with its AI-driven coronary assessments.
The feed also features announcements about payer coverage and coding, including coverage decisions by major U.S. insurers and information on Category I CPT coding for Heartflow Plaque Analysis. These updates provide context on how access to Heartflow’s non-invasive plaque quantification and coronary physiology tools is evolving within healthcare systems.
In addition, visitors can review Heartflow’s participation in major cardiology and healthcare conferences, such as scientific sessions hosted by the American Heart Association, the European Association of Cardiovascular Imaging, and large investor and industry meetings. These items typically summarize late-breaking data presentations, new product introductions, and company commentary on the role of AI in precision cardiovascular care. Investors, clinicians, and other stakeholders can use this page as a centralized source for ongoing developments related to HTFL and its CAD-focused health information services.
Heartflow (NASDAQ: HTFL), an AI technology company focused on coronary artery disease (CAD), has announced the pricing of its upsized IPO. The company is offering 16,666,667 shares at $19.00 per share, expecting to raise approximately $316.7 million in gross proceeds.
Trading will commence on August 8, 2025, on the Nasdaq Global Select Market. The underwriters have a 30-day option to purchase up to 2.5 million additional shares. The IPO is expected to close on August 11, 2025, with J.P. Morgan, Morgan Stanley, and Piper Sandler serving as joint book-running managers.
Heartflow (NYSE:HTFL) announced that UnitedHealthcare, the largest commercial insurer in the United States, will provide nationwide coverage for its AI-enabled Heartflow Plaque Analysis across all business lines. The coverage, effective October 1, 2025, will include Commercial, Medicare Advantage, and Community plans.
The FDA-cleared technology, showing 95% agreement with gold standard IVUS, helps diagnose and manage coronary artery disease (CAD). Clinical outcomes from the DECIDE registry demonstrated that management changes guided by Heartflow Plaque Analysis resulted in an average LDL cholesterol decrease of 18.7mg/dL, associated with a 15% reduction in cardiac event risk.